NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ribometrix

Ribometrix

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://ribometrix.com/

Last Round

Strategic

Jan 6, 2021

Total Funding Raised

$45.79M

Company Overview

Ribometrix is a biotechnology company that develops small molecule therapeutics designed to modulate RNA biology for the treatment of human diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

RNA-targeted therapeuticssmall-molecule discoveryRNA therapeuticsundruggable targetsdrug discovery platformstructural biologycomputational chemistryRNA-targeted drugsbiotech R&Dhigh-throughput screeningsmall molecule drugRNA-targetingdrug discovery biotechRNA drug discoverynext-gen therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ribometrix Comps

Public and private peers based on sector, stage, and business model.

Ribometrix comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ribometrix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJan 6, 2021
StrategicSep 30, 2019
Series A ExtensionSep 27, 2019
Series ANov 13, 2018
SeedOct 31, 2017

Key People

Founding team and executive leadership

Katie Warner

Chief Scientific Officer, Co-Founder

Founding Team

Ribometrix Investors

Notable investors and investment history

Ribometrix investors
InvestorRounds
SV Health InvestorsSeries A, Series A Extension, Seed
A. M. Pappas & AssociatesSeries A
MP Healthcare Venture ManagementSeed, Series A
NIH RADxGrant
GenentechStrategic
M VenturesSeries A
Hatteras Venture PartnersSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 9, 2025

    Katie Warner appointed as new Chief Scientific Officer.

  • Jan 9, 2025

    William S. Marshall, Ph.D. named new Chief Executive Officer.

Ribometrix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ribometrix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ribometrix's valuation, stock price, and market status.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range21
Year Founded2014
Last FundingJan 6, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.